Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference37 articles.
1. Cyclin‐dependent kinase inhibitors for the treatment of breast cancer: past, present, and future;DiPippo;Pharmacotherapy: J. Hum. Pharmacol. Drug Ther.,2016
2. Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer;Barroso-Sousa;Breast Care,2016
3. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study;Curigliano;Breast,2016
4. A phase I study of the CDK4/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors;Geoerger;Clin. Cancer Res.,2017
5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf, (accessed on November 2019).
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献